首页> 外国专利> NOVEL TUMOR-SPECIFIC ANTIGENS FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND USES THEREOF

NOVEL TUMOR-SPECIFIC ANTIGENS FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND USES THEREOF

机译:用于急性淋巴细胞白血病(全部)的新型肿瘤特异性抗原及其用途

摘要

Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.
机译:急性淋巴细胞白血病(全部)没有受益于创新的免疫治疗,主要是因为缺乏可行的免疫目标。 本文描述了由所有细胞特异性表达的新型肿瘤特异性抗原(TSAs)。 本文所述的大多数TSA来自异常表达的未出现的未经化的基因组序列,例如内部内肠道和非基因序列,其在正常组织中不表达。 描述了核酸,组合物,细胞,抗体和源自这些TSAs的疫苗。 还描述了使用TSA,核酸,组合物,抗体,细胞和疫苗来治疗诸如所有人的白血病。

著录项

  • 公开/公告号WO2021207826A1

    专利类型

  • 公开/公告日2021-10-21

    原文格式PDF

  • 申请/专利权人 UNIVERSITÉ DE MONTRÉAL;

    申请/专利号WO2021CA50471

  • 申请日2021-04-09

  • 分类号C07K14/47;A61K39;A61K39/395;A61K9/127;A61P35/02;A61P37/04;C07K14/725;C07K14/74;C07K16/18;C07K16/28;C07K16/46;C07K17/02;C07K7/06;C12N5/078;C12N5/10;

  • 国家 CA

  • 入库时间 2022-08-24 21:52:01

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号